Aastrom Biosciences, Inc.
Stem cell technology company reports loss of $0.03 per share
Published in Healthcare Mergers, Acquisitions and Ventures Week, October 15th, 2005
Commenting on the year, R. Douglas Armstrong, PhD, CEO and Chairman of Aastrom, said, "We made significant strides in fiscal year 2005 and demonstrated our continued commitment to achieve progressive corporate milestones. Of particular note has been the movement of our TRCs into the clinic, and the interim results we have achieved in these patient treatments.
The support and interest that we are receiving from the medical field as well as regulatory agencies, should further our clinical progress as we expand our trials and move...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- Abaris, Inc.
IT company establishes life science division for pharma firms - Access Pharmaceuticals, Inc.
Polymer therapeutics developer reports status of cash position - Aceto Corp.
Pharmaceutical distributor reports income of $0.11 per share - Advanced Cell Technology
Stem cell technology firm raises $17.75M in private placements - AmerisourceBergen Corp.
Drug distribution firm completes sale of $900M in senior notes - AtriCure, Inc.
Surgical device maker reports 50.9% increase in revenue - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
